Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v2.4.0.8
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
3 Months Ended 137 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Mar. 31, 2014
COSTS AND EXPENSES:      
Research and development $ 1,715,307 $ 1,590,613 $ 34,503,195
General and administrative 1,087,035 1,121,703 18,826,512
Restructuring costs 16,882 0 1,113,756
Merger costs 0 0 799,133
Total costs and expenses 2,819,224 2,712,316 55,242,596
LOSS FROM OPERATIONS (2,819,224) (2,712,316) (55,242,596)
OTHER INCOME (EXPENSE):      
Grant income 0 0 244,479
Gain (loss) on revaluation of derivative warrants (54,945) 6,043 2,272,984
Loss on issuance of derivative warrants 0 (744,957) (744,957)
Interest expense, net (69,244) (2,649) (534,052)
Other income 0 0 1,161
Total other income (expense), net (124,189) (741,563) 1,239,615
NET LOSS (2,943,413) (3,453,879) (54,002,981)
DEEMED DIVIDEND ON WARRANTS 0 0 (543,359)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS $ (2,943,413) $ (3,453,879) $ (54,546,340)
BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE (in dollars per share) $ (0.05) $ (0.07) $ (2.93)
SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE (in shares) 57,397,997 51,286,886 18,647,994